CClinicalTrials.gg
Status unknownNCT02598401BONESUpdated Apr 17, 2019

The British Osteonecrosis Study

An observational study in Osteonecrosis, sponsored by University of Leeds. Status unknown at 4 sites in United Kingdom. Open to participants aged 10 Years to 25 Years. Per ClinicalTrials.gov, last updated 2019-04-17.

Sponsored by University of Leeds · Observational

The sponsor has not verified this record recently (last verified Apr 2019), so the status shown — last known as Recruiting — may be out of date.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
50
Ages
10 Years to 25 Years
Sex
All
01

Study summary

The aim of this research is to examine the natural history of osteonecrosis in older children, teenagers and young adults with acute lymphoblastic leukaemia and lymphoblastic lymphoma within the UK. In addition to using and validating new, internationally agreed, standard definitions for osteonecrosis, this study will provide the data needed to develop a radiological classification which correlates with clinical status.

Read the detailed description

Children, teenagers or young adults between the age of 10 (including the day of the 10th birthday) and 24 years 364 days (at the time of diagnosis) with a first diagnosis of acute lymphoblastic leukaemia or lymphoblastic lymphoma (T-NHL or SmIg negative precursor B-NHL) diagnosed under standard criteria are eligible for BONES.

The recruitment target is 50 over a 2 year period, which is based on an anticipated ascertainment target of 75%.

Information will be collected on basic demographics, presenting features and diagnosis at initial recruitment. Further data will be collected at the end of induction to ascertain treatment and response, along with results of relevant investigations performed in induction detailed below. Clinical information collected will include height, weight and puberty stage. At the four subsequent time points when MRI imagine is performed further data will also be collected, including a physiotherapy assessment using a structured assessment tool and child health assessment questionnaire, and biochemical information.

Investigations

The results of the following investigations, usually performed as part of the routine assessment, will be collected:

  1. At diagnosis - highest white cell count, immunophenotype, cytogenetics, molecular results; albumin; lipid profile; vitamin D level, PTH, bone profile
  2. At the end of induction - MRD result, flow cytometry from end of induction bone marrow; albumin; lipid profile plus results of additional investigations of vitamin D, PTH and bone profile if performed.

DEXA scans should be performed on all children >10y old and on treatment for ALL. It is recommended that a DEXA scan is performed at diagnosis and then annually. The results of these DEXA scans will be collected.

MRI of the hips, knees and ankles should comprise of unenhanced coronal T1 and STIR images as a minimum protocol. Knees and ankles can be imaged together. Where further information of a specific joint is needed pre-treatment additional sequences in different planes could be performed at the discretion of the participating centre. MRI will be performed at the following time points:

  1. Within 4 weeks of diagnosis
  2. At the end of delayed intensification
  3. One year after the start of maintenance
  4. Two years after the start of maintenance
  5. Three years after the start of maintenance

In the event of the development of osteonecrosis the patient should be managed according to local protocols and at the discretion of their own consultant. Information on treatment will be collected.

Radiological review:

A central review panel consisting of Paediatric Radiologists with an interest in paediatric haematology will meet quarterly to review each MRI in order to agree the grade of osteonecrosis and noting specific features according to the study radiology proforma.

02

Conditions studied

  • Osteonecrosis

Browse trials for

03

In context

Osteonecrosis

184 studies on the registry are indexed under Osteonecrosis; 33 are open to participants now.

This study's planned enrollment of 50 is below the median of 149 across 81 observational studies indexed under Osteonecrosis.

Browse Osteonecrosis studies →

Lead sponsor

University of Leeds is the lead sponsor of 200 studies on the registry; 25 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
10 Years to 25 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Children, teenagers or young adults between the age of 10 (including the day of the 10th birthday)and 24 years 364 days (at the time of diagnosis) with a first diagnosis of acute lymphoblastic leukaemia or lymphoblastic lymphoma (T-NHL or SmIg negative precursor B-NHL) diagnosed under standard criteria are eligible for BONES.

Inclusion criteria

  • first diagnosis of acute lymphoblastic leukaemia or lymphoblastic lymphoma (T-NHL or SmIg negative precursor B-NHL)

Exclusion criteria

Exclusion Criteria:

  • inability to have MRI scans of lower limbs
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
50 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Interventions

  • Otherobservation

    Observational study with no intervention

06

What researchers measure

Primary outcomes

  1. Incidence of osteonecrosis

    The incidence of osteonecrosis in older children, teenagers and young adults being treated for acute lymphoblastic leukaemia (ALL) in the UK at different time points in their treatment.

    Time frame: 5 years

Secondary outcomes

  1. Risk factors for development of osteonecrosis.

    The risk factors for progression and the development of symptomatic osteonecrosis in this population.

    Time frame: 5 years

  2. Radiological features for prediction of progression of osteonecrosis

    specific radiological features that predict for either progression or regression in those with asymptomatic osteonecrosis

    Time frame: 5 years

07

Study locations

3 of 4 sites recruiting
  • Birmingham Children's Hospital
    Birmingham, B4 6NH, United Kingdom
    Not yet recruiting
  • Leeds Children's Hospital
    Leeds, LS2 9NS, United Kingdom
    Recruiting
  • St James's University Hospital
    Leeds, LS9 7TF, United Kingdom
    Recruiting
  • Southampton Children's Hospital
    Southampton, SO16 6YD, United Kingdom
    Recruiting
08

References and documents

Publications

  • Amin N, Kinsey S, Feltbower R, Kraft J, Whitehead E, Velangi M, James B. British OsteoNEcrosis Study (BONES) protocol: a prospective cohort study to examine the natural history of osteonecrosis in older children, teenagers and young adults with acute lymphoblastic leukaemia and lymphoblastic lymphoma. BMJ Open. 2019 May 22;9(5):e027204. doi: 10.1136/bmjopen-2018-027204. PubMed 31122988 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 17, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02598401
Lead sponsor
University of Leeds
Responsible party
Nadia laila Amin (Chief Investigator, University of Leeds) — Principal investigator
First posted
Nov 5, 2015
Start date
Aug 21, 2017
Primary completion
Apr 10, 2022 (estimated)
Completion
Oct 10, 2022 (estimated)
Last update
Apr 17, 2019

Study contacts

Nadia L Amin, MBChB
Contact
nadia.amin3@nhs.net
0113 343 2596
Beki James, PhD
Contact
beki.james@nhs.net
01133928779
Nadia L Amin, MBChB
principal investigator · University of Leeds

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Apr 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion